Bortezomib

Reversibly inhibits 26S proteasome chymotrypsin-like activity, disrupting protein homeostasis

• ·Multiple Myeloma, Newly Diagnosed
• ·Multiple Myeloma
• ·DS Stage I Multiple Myeloma
• ·DS Stage II Multiple Myeloma
• ·DS Stage III Multiple Myeloma

No curated interaction pairs are recorded for Bortezomib. This is not a statement that none exist — check a full interaction reference before combining.

• Peripheral neuropathy
• Thrombocytopenia
• Nausea
• Diarrhea
• Fatigue

Half-life

9-15 hours

Protein binding

83%

Metabolised by

CYP3A4, CYP2C19, CYP1A2

Not recorded for Bortezomib. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.